CN Stock MarketDetailed Quotes
600422 KPC Pharmaceuticals, Inc.
Watchlist
21.38
+0.29+1.38%
Market Closed 12/01 15:00 CST
21.48High20.97Low89.45KlotVolume
21.06Open21.09Pre Close190.34MTurnover1.18%Turnover Ratio40.88P/E (TTM)16.21BMarket Cap25.9352wk High42.25P/E (Static)757.99MShares13.1852wk Low3.09P/B16.18BFloat Cap25.93Historical High23.20Limit Up756.98MShs Float-0.40Historical Low18.98Limit Down2.42%Amplitude31.31KlotAsk0.16Dividend TTM21.28Avg Price54.82KlotBid0.75%Div YieldTTM100Lot Size
KPC Pharmaceuticals, Inc. Key Stats
All
YOY

(Q9)2023/09/30 | (Q6)2023/06/30 | (Q3)2023/03/31 | (FY)2022/12/31 | (Q9)2022/09/30 | (Q6)2022/06/30 | (Q3)2022/03/31 | (FY)2021/12/31 | (Q9)2021/09/30 | (Q6)2021/06/30 | |
---|---|---|---|---|---|---|---|---|---|---|
Total operating revenue | -9.40%5.61B | -10.81%3.77B | -19.19%1.91B | 0.35%8.28B | 2.74%6.19B | 3.28%4.23B | 24.71%2.36B | 6.95%8.25B | 11.13%6.03B | 19.54%4.09B |
Operating revenue | -9.40%5.61B | -10.81%3.77B | -19.19%1.91B | 0.35%8.28B | 2.74%6.19B | 3.28%4.23B | 24.71%2.36B | 6.95%8.25B | 11.13%6.03B | 19.54%4.09B |
Other operating revenue | ---- | -73.13%137.42M | ---- | 169.31%562.24M | ---- | 643.75%511.52M | ---- | 88.48%208.77M | ---- | -12.95%68.78M |
Total operating cost | -10.73%5.17B | -11.99%3.5B | -20.64%1.74B | 0.08%7.84B | 1.83%5.79B | 4.13%3.97B | 23.46%2.2B | 7.53%7.83B | 12.18%5.68B | 19.32%3.82B |
Operating cost | -12.87%3.08B | -16.50%2.07B | -29.56%1.07B | -0.02%4.84B | 1.14%3.54B | 5.99%2.48B | 39.33%1.51B | 10.44%4.84B | 16.64%3.5B | 22.02%2.34B |
Operating tax surcharges | 2.83%54.07M | 1.27%35.15M | 11.55%15.88M | 11.16%72.22M | 13.77%52.58M | 5.60%34.71M | 4.56%14.24M | 0.73%64.97M | -0.20%46.22M | 12.56%32.87M |
Operating expense | -3.86%1.74B | -1.34%1.19B | 1.16%550.04M | 2.49%2.43B | 3.03%1.81B | 0.64%1.2B | -4.24%543.72M | 3.26%2.37B | 3.91%1.76B | 14.86%1.2B |
Administration expense | -15.64%233.99M | -5.64%163.71M | 2.42%88.66M | -6.56%379.07M | -1.46%277.35M | -4.85%173.48M | 2.92%86.57M | 10.66%405.67M | 14.66%281.47M | 16.03%182.33M |
Financial expense | -71.15%9.46M | -74.89%5.8M | -34.36%6.48M | -3.48%38.31M | 26.69%32.79M | 62.33%23.1M | 310.32%9.88M | 9.89%39.69M | 20.60%25.88M | 7.27%14.23M |
-Interest expense (Financial expense) | -61.17%11.35M | -21.94%14.38M | -14.86%6.89M | 21.27%40.73M | 53.59%29.24M | 62.29%18.42M | 81.22%8.09M | 15.17%33.59M | -20.44%19.04M | -26.98%11.35M |
-Interest Income (Financial expense) | 27.92%-2.67M | -158.13%-6.06M | -315.61%-2.67M | -11.31%-6.07M | -8.36%-3.7M | 12.05%-2.35M | 48.97%-641.57K | 29.17%-5.45M | 18.54%-3.42M | 21.34%-2.67M |
Research and development | -41.29%43.33M | -43.93%30.58M | -43.45%16.51M | -30.71%69.65M | 2.12%73.79M | 16.43%54.53M | 14.68%29.19M | -21.75%100.52M | 18.32%72.26M | 28.71%46.84M |
Credit Impairment Loss | 2.07%-40.93M | 18.72%-28.51M | 24.14%-24.97M | -25.60%-43.15M | -54.45%-41.8M | -53.20%-35.08M | -624.01%-32.92M | -216.64%-34.35M | -191.35%-27.06M | -1,608.71%-22.9M |
Asset Impairment Loss | 62.48%-13.81M | 70.03%-10.93M | -722.51%-5.41M | -239.11%-67.59M | -1,198.46%-36.81M | -4,662.71%-36.47M | ---657.65K | 10.74%-19.93M | 260.67%3.35M | -313.20%-765.84K |
Other net revenue | -49.92%31.03M | -38.31%9.09M | 115.66%3.69M | -75.86%50.6M | -66.14%61.96M | -88.40%14.73M | -119.32%-23.58M | 100.37%209.6M | 159.11%182.99M | 153.42%126.96M |
Fair value change income | -117.44%-6.6M | -109.40%-3.56M | ---5.37M | 1,212.29%10.67M | --37.84M | --37.84M | ---- | 29.39%-959.58K | ---- | ---- |
Invest income | 78.43%15.45M | 425.06%13.56M | 734.14%24.36M | -96.03%5.98M | -93.53%8.66M | -98.00%2.58M | -103.23%-3.84M | 857.73%150.65M | 996.21%133.91M | 2,206.63%129.23M |
-Including: Investment income associates | -143.19%-416.47K | 84.05%-150.34K | -119.81%-49.24K | 45.59%-254.87K | 521.51%964.32K | -2,004.15%-942.78K | 0.00%-22.4K | 93.39%-468.42K | 88.50%-228.78K | 97.40%-44.81K |
Asset deal income | 467.75%1.52M | 515.87%1.25M | 573.32%1.24M | 590.97%15.21M | -71.40%268.34K | -35.78%203.28K | 14,169.17%184.21K | -95.71%2.2M | -69.54%938.22K | -88.99%316.53K |
Other revenue | -19.62%75.4M | -18.36%37.28M | 1.40%13.84M | 15.61%129.47M | 30.54%93.81M | 116.68%45.66M | 78.48%13.65M | 55.27%112M | 12.83%71.86M | -50.54%21.07M |
Operating profit | 1.77%476.44M | 5.27%282.12M | 19.14%169.61M | -21.59%497.15M | -11.34%468.17M | -33.55%268M | -40.00%142.36M | 17.24%634.05M | 23.14%528.03M | 46.35%403.29M |
Add:Non operating Income | 365.63%7.64M | 450.37%6.82M | -14.49%311.87K | 89.53%2.79M | 143.92%1.64M | 173.08%1.24M | 64.71%364.7K | -81.08%1.47M | -81.09%672.99K | -77.04%453.69K |
Less:Non operating expense | 134.63%7.31M | 229.46%5.51M | 798.73%1.6M | 435.61%22.65M | -18.33%3.11M | -4.85%1.67M | -58.15%177.92K | -47.89%4.23M | -46.56%3.81M | -71.51%1.76M |
Total profit | 2.16%476.78M | 5.93%283.43M | 18.09%168.32M | -24.39%477.29M | -11.09%466.7M | -33.44%267.57M | -39.87%142.55M | 16.80%631.29M | 23.43%524.89M | 48.13%401.99M |
Less:Income tax cost | -6.81%80.55M | 7.54%52.9M | 33.09%34.11M | -22.23%91.83M | -1.20%86.44M | -26.14%49.19M | -35.56%25.63M | 50.79%118.07M | 19.91%87.49M | 50.48%66.61M |
Net profit | 4.20%396.23M | 5.56%230.53M | 14.80%134.21M | -24.89%385.46M | -13.06%380.26M | -34.89%218.37M | -40.74%116.91M | 11.04%513.21M | 24.16%437.4M | 47.68%335.38M |
Net profit from continuing operation | 4.20%396.23M | 5.56%230.53M | 14.80%134.21M | -24.89%385.46M | -13.06%380.26M | -34.89%218.37M | -40.74%116.91M | 11.04%513.21M | 24.16%437.4M | 47.68%335.38M |
Less:Minority Profit | 34.91%10.22M | 304.00%7.16M | 30.19%3.18M | -58.97%2.28M | 114.12%7.57M | -46.55%1.77M | 2.37%2.45M | 4.13%5.55M | 178.33%3.54M | 32.53%3.31M |
Net profit of parent company owners | 3.58%386.01M | 3.12%223.37M | 14.47%131.03M | -24.52%383.18M | -14.10%372.68M | -34.77%216.6M | -41.27%114.47M | 11.12%507.67M | 23.61%433.86M | 47.84%332.07M |
Earning per share | ||||||||||
Basic earning per share | 4.08%0.51 | 0.00%0.29 | 13.33%0.17 | -23.88%0.51 | -14.37%0.49 | -33.77%0.29 | -41.63%0.15 | 11.33%0.67 | 23.67%0.5722 | 48.34%0.4379 |
Diluted earning per share | 4.08%0.51 | 0.00%0.29 | 13.33%0.17 | -23.88%0.51 | -14.37%0.49 | -33.77%0.29 | -41.63%0.15 | 11.33%0.67 | 23.67%0.5722 | 48.34%0.4379 |
Other composite income | -108.99%-1.09M | -94.27%600.37K | 83.72%-266.17K | 334.75%15.79M | 1,317.04%12.07M | 2,032.96%10.48M | -535.25%-1.63M | -45.53%-6.73M | -171.71%-991.87K | -136.88%-542.2K |
Other composite income of parent company owners | -108.99%-1.09M | -94.12%615.93K | 83.72%-266.17K | 340.78%15.82M | 1,317.04%12.07M | 2,032.96%10.48M | -535.25%-1.63M | -33.47%-6.57M | -172.46%-991.87K | -137.29%-542.2K |
Other composite income of minority owners | ---- | ---15.57K | ---- | 81.15%-29.44K | ---- | ---- | ---- | -151.98%-156.23K | ---- | ---- |
Total composite income | 0.72%395.14M | 0.99%231.13M | 16.19%133.95M | -20.78%401.25M | -10.10%392.33M | -31.65%228.86M | -41.68%115.28M | 10.69%506.49M | 23.40%436.41M | 46.49%334.84M |
Total composite income of parent company owners | 0.04%384.92M | -1.36%223.99M | 15.89%130.76M | -20.37%399M | -11.12%384.75M | -31.50%227.08M | -42.22%112.83M | 10.88%501.1M | 22.84%432.87M | 46.65%331.53M |
Total composite income of minority owners | 34.91%10.22M | 303.12%7.14M | 30.19%3.18M | -58.33%2.25M | 114.12%7.57M | -46.55%1.77M | 2.37%2.45M | -4.21%5.39M | 175.26%3.54M | 31.68%3.31M |
Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
Audit Opinions | -- | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- | -- |
Auditor | -- | -- | -- | Ernst & Young (Special General Partnership) | -- | -- | -- | China Audit Zhonghuan Certified Public Accountants (Special General Partnership) | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.